|
Balance Sheet Cash Flow Statement 2929 7th St., Ste. 100 Berkeley, CA 94710-2753 CA Tel. 510-848-5100 Fax 510-848-1327 |
Type: Public
On the web:
http://www.dynavax.com
Employees:
155
Employee growth: (10.4%)
Dynavax Technologies is trying to reprogram the way the body reacts to disease. The firm focuses on immunostimulatory sequences (ISS), short strands of DNA found to strengthen the immune system. The company's lead candidate in clinical trials is HEPLISAV, a hepatitis B vaccine. Dynavax is working on other candidates that might lead to treatments for asthma, colorectal cancer, and hepatitis C. Partnerships are key to its work with other candidates. Dynavax has partnered with AstraZeneca to research preclinical work on a treatment for asthma and chronic obstructive pulmonary disease, while Symphony Dynamo has poured in money to fund the company's colorectal cancer and hepatitis C research.
Key numbers for fiscal year ending December, 2008:
Sales: $37.1M
One year growth: 163.2%
Net income: ($20.8)M
Officers:
Chairman: Arnold L. (Arnie) Oronsky
President, CEO, and Director: Dino Dina
Senior Director Investor Relations and Corporate Communications: Amy Figueroa
Competitors:
Bristol-Myers Squibb
GlaxoSmithKline
Merck
